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bodily anxiety or restlessness with QTP (OR 0.506, 95%CrI:
0.290, 0.789), decrease in EPS with QTP (OR 0.441, 95%CrI:
0.129, 0.910), increase in weight gain with OLZ (OR 2.139,
95%CrI: 1.764, 2.626), and decrease in weight gain with ZPD
(OR 0.466, 95%CrI: 0.317, 0.657). CONCLUSIONS: The
results of this systematic review paint a complex picture akin to
the nature of schizophrenia and bipolar disorder, reinforcing the
importance of treatment choice. To achieve optimal outcomes,
physicians need to consider efﬁcacy and tolerability together with
the patient’s psychiatric history, preferences and values when
making treatment decisions.
PMH10
TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE
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OBJECTIVES: In 2002, the National Institute for Health and
Clinical Excellence (NICE) highlighted extrapyramidal symp-
toms (EPS), sexual dysfunction, sedation, and weight gain, as
the outcomes considered by patients taking atypical antipsy-
chotics to be the most troublesome. This research was designed
to compare the tolerability of the new extended release que-
tiapine to the existing quetiapine immediate release formulation
on these outcomes in addition to orthostatic hypotension,
which could be a signiﬁcant cause of morbidity. METHODS: A
meta-analysis of the four regulatory randomised controlled
trials (Study 041, 133, 132 and 146) comparing quetiapine
extended release with the immediate release formulation using
a ﬁxed effect model. Summary effect estimate was calculated as
relative risk (RR) with 95% conﬁdence interval (95% CI)
where RR < 1 favours extended release and RR > 1 favours
immediate release. All comparisons were conducted on a
mg-for-mg basis (300 mg, 400 mg 600 mg and 800 mg) for the
two formulations. Statistical heterogeneity was tested for using
a chi-square test. A sensitivity analysis was conducted using a
random effects model. RESULTS: All outcomes were measured
consistently in the trials included in the analyses. There were no
signiﬁcant differences between the two formulations of quetiap-
ine for any outcomes assessed. Individual results were as
follows: EPS RR 1.067 (95%CI: 0.694 to 1.641; p = 0.767);
orthostatic hypotension RR 1.089 (95%CI: 0.744 to 1.595;
p = 0.661); sedation RR 0.781 (95%CI: 0.569 to 1.073;
p = 0.128); weight gain RR 0.784 (95%CI: 0.521 to 1.180; p =
0.244); prolactin RR 0.708 (95%CI: 0.465 to 1.077; p =
0.107). Signiﬁcant heterogeneity was not detected in any com-
parison (all p > 0.42) and the effect of using a random effects
model made no difference to the summary effect estimates.
CONCLUSIONS: The meta-analysis suggests that the tolerabil-
ity proﬁle of extended release quetiapine is consistent with that
of the immediate release formulation.
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OBJECTIVES: By testing a methodology that combines labelled
and non-labelled public expenditure, this report aims to produce
ﬁrst estimates of the amounts European governments spend on
the illegal drug problem. METHODS: The European Informa-
tion Network on Drugs and Drug Addiction (REITOX) was
asked to list any budgeted labelled drug-related fund found after
reviewing government budgets for the year 2005 in 30 countries.
In order to ensure consistency in comparing ﬁgures over time and
across countries, labelled expenditure was classiﬁed according to
the International Classiﬁcation of the Functions of Government
(COFOG). Since not all drug-related expenditure is identiﬁed as
such in budgets, modelling approaches were used to estimate
the amount embedded in other programmes and interventions.
Non-labelled drug-related expenditure was obtained by using a
top-down costing approach to estimate the proportion of expen-
diture causally attributable to drug use. Wherever possible,
REITOX explored feasible deﬁnitions of ‘attributable propor-
tions’ for estimating non-labelled drug-related expenditure under
two COFOG functions: public order and safety and health.
RESULTS: On the whole, countries have a considerable amount
of quality information available on this type of costs, although
calculating the non-labelled constituent is often an arduous task.
Estimates from reporting countries extrapolated to European
level arrived at a total cost of drug-related public expenditure in
2005 of €34 billion, which is equivalent to 0.3% of the sum of
the GDP of all of the countries. This represents an average
expenditure of €60 per European citizen per year. CONCLU-
SIONS: Whilst such ﬁgures should still be used with caution (the
methodology still needs reﬁning and country data is in no way
uniform), one observation the report makes is that the disburse-
ments identiﬁed mainly refer to public expenditure made at
central government level. The future inclusion of sub-national
government expenditure will certainly increase the amounts of
public expenditure estimated.
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Cost containment in Germany is to a large extent regulated by
ﬁxed doctor’s budgets (Richtgrößen) for treatment of patients in
statutory health insurance (SHI). With Olanzapine (OLA) and
oral Risperidone (RIS) two of the most often used second gen-
eration antipsychotics (SGA) lost patent in 2007. Generic substi-
tution could lead to signiﬁcant cost savings. OBJECTIVES: Aim
of this database analysis was to estimate the budget impact of
prescribing generic OLA and RIS and to evaluate the potential
for a more individualized therapy in schizophrenia without
exceeding budgets. METHODS: Using the IMS Disease Analyzer
based on the electronic medical records of 112 psychiatrist prac-
tices in Germany, a retrospective analysis of drug expenditures
for schizophrenia was conducted. As reference data from QIV
2007 were used. Budget impact was then estimated based on a
scenario assuming generic prices being 20% (RIS) or 30% (OLA)
of original and an overall generic patient share of 80%.
RESULTS: Data of 93.844 SHI-insured patients were analyzed,
65.028 of those with drug prescriptions in QIV 2007. Mean drug
expenditures per patient in QIV 2007 was €195.52.7% of drug
expenditures of psychiatrists could be explained by SGA pre-
scriptions. A total of 55.1% of their patients treated with SGA
received either RIS or OLA. This corresponded to 49.3% of costs
for SGA. The estimated budget impact according to the scenario
is a cost saving of 25.6% of the drug expenditure for SGA.
CONCLUSIONS: Especially in schizophrenia there is a need for
therapy optimization according to current treatment guidelines
and as also aspired by payers. As the data show, there is a
signiﬁcant cost saving potential from use of generic SGA. These
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savings provide the opportunity for a more individualized
therapy in those schizophrenic patients who are in need of and
without budget overspend.
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OBJECTIVES: 1) To assess cost-utility of sertindole (Serdolect®)
compared with commonly used antipsychotic drugs in
Poland—haloperidol and risperidone in the treatment of schizo-
phrenia, and 2) To assess the ﬁnancial consequences of sertindole
reimbursement for Polish National Health Fund (NHF)
budget.—haloperidol and risperidone in the treatment of schizo-
phrenia, and 2) To assess the ﬁnancial consequences of sertindole
reimbursement for Polish National Health Fund (NHF) budget.
METHODS: Cost-utility decision model comparing three phar-
macotherapy strategies in the treatment of chronic schizophrenia
(sertindole, risperidone, haloperidol) was developed. Payer per-
spective for health services (NHF budget and patient) and one-
year time horizon were undertaken. Measure of effectiveness was
expressed in quality adjusted life years (QALYs). Data on clinical
efﬁcacy based on published literature. Main parameters of the
model were: compliance, clinical response, recurrence, adverse
events, cost parameters (eg. drugs, AEs, treatment in hospital and
outpatient setting, GP) and disutilities associated with AEs and
relapse. Budget impact analysis was performed in a 5-year
horizon following Serdolect® introduction. RESULTS: In one-
year horizon, incremental cost of QALY saved (ICER) was:
PLN14,117 (sertindole vs. risperidone) and PLN56,044 (sertin-
dole vs haloperidol). The sensitivity analyses showed the robust-
ness of the results. Based on ﬁve year budget forecast, public
payer expenditures on atypical antipsychotic drugs would
increase by 0.005% (PLN13,478) in year one and by 0.118%
(PLN402,243) in year ﬁve of Serdolect® reimbursement. CON-
CLUSIONS: ICERs indicate that sertindole is a cost-effective
strategy compared to risperidone and haloperidol in the treat-
ment of chronic schizophrenia in Poland. Reimbursement of
Serdolect® would result in a minor increase in Polish NHF
expenditures. Reimbursement of Serdolect® would result in a
minor increase in Polish NHF expenditures.
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OBJECTIVES: Compare the cost-effectiveness of quetiapine
extended-release versus olanzapine, in patients with ﬁrst episode
schizophrenia who have failed on generic risperidone.
METHODS: A one-year, decision analytic model populated with
appropriate published efﬁcacy data together with drug acquisi-
tion and resource use costs, was employed to illustrate the pos-
sible consequences of treatment with generic risperidone
followed by either olanzapine or quetiapine extended-release.
The perspective taken was that of the UK National Health
Service. The clinical outcomes measured and compared were:
discontinuation due to clinical reasons; response; relapse;
number of patients effectively managed; and those requiring
further intervention. An assumption was made that quetiapine
extended-release would deliver the same outcomes as the instant-
release formulation in this population. The doses applied (ris-
peridone 3.3mg, olanzapine 15.7mg and quetiapine extended-
release 646 mg) were the mean doses observed in the clinical
trials. RESULTS: Relative to olanzapine more patients were
effectively managed on quetiapine (5%). The total cost per effec-
tively managed patient was estimated to be higher for olanzapine
compared to quetiapine (£21,658 and £20,955 respectively).
Quetiapine also had fewer patients that: discontinued due to
clinical reasons; failed to respond; relapsed; or required addi-
tional intervention relative to olanzapine (28%, 5%, 9% and
13% respectively). CONCLUSIONS: Not all atypical-naive
patients that receive generic risperidone will tolerate or respond
adequately to therapy and for those patients that require subse-
quent treatment with an atypical antipsychotic, quetiapine
extended-release is a cost-effective second-line treatment choice
compared to olanzapine. The analysis is limited by the lack of
comparative data in this population. The effectiveness of que-
tiapine extended-release was assumed to be the same as the
instant-release formulation, however, due to a less complicated
and shorter titration regimen allowing therapeutic dose to be
reached much sooner, quetiapine extended-release may have
added beneﬁt via a positive impact on patient compliance and
psychosis management.
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OBJECTIVES: To assess the cost-effectiveness of quetiapine
(QTP) in combination with lithium (Li) or divalproex (DVP)
(QTP+Li/DVP) in comparison with placebo in combination with
lithium or divalproex (Li/DVP alone) in the maintenance treat-
ment of bipolar I disorder. METHODS: A Markov decision-
analytic model was developed to estimate the relative costs and
outcomes associated with QTP+Li/DVP compared with Li/DVP
alone from the perspective of the UK National Health Service.
Model parameters and transition probabilities were derived from
2 identical randomized, double-blind clinical trials of up to 104
weeks’ duration and with a combined ITT patient population of
1326 (Trials 126 and 127). The Markov model followed, over 2
years, 1000 hypothetical patients (receiving either QTP+Li/DVP
or Li/DVP alone) with bipolar I disorder in remission, where each
patient could move through 1 of 4 mood states (euthymia,
mania, depression, or no active therapy) through 8 quarterly
cycles. During each cycle, a patient accumulated costs and out-
comes and faced a probability of transitioning to another mood
state. The reference year was 2007 and the discount rate was
3.5%. RESULTS: Compared with Li/DVP alone, QTP+Li/DVP
signiﬁcantly reduced the number of acute mood events per
patient per year from 0.92 to 0.42 with an ICER of £506 per
acute mood event averted. QTP+Li/DVP was also associated
with reductions of 54% and 55% in rates of acute mania and
depression events, a 25% reduction in hospitalizations related to
acute mania, and a 38% reduction in hospitalizations related to
acute depression, all leading to a 29% reduction in hospitaliza-
tion costs. The incremental cost per QALY gained for QTP+Li/
DVP treatment was £7453. Sensitivity analyses found the results
to be robust. CONCLUSIONS: QTP+Li/DVP is cost-effective
and has potential beneﬁts derived from reduced hospitalizations
associated with acute mood events, compared with Li/DVP
alone.
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